Compare prices and buy Mazdutide from 8 research peptide vendors - also called suppliers or sources. Updated daily.
A 34-residue dual agonist of the GLP-1 and glucagon receptors (CAS 2259884-03-0), described by its developers as an oxyntomodulin analog and acylated with a C20 fatty diacid. Developed by Eli Lilly as LY3305677 and in China by Innovent Biologics as IBI362. Innovent reports approval by China's NMPA for chronic weight management and for glycemic control in type 2 diabetes. It is not FDA-approved, and Lilly's trials outside China have reached Phase 2.
For research purposes only. Not medical advice.
Mazdutide (Eli Lilly's LY3305677, developed in China by Innovent Biologics as IBI362) is a synthetic peptide that activates two receptors: the GLP-1 receptor, the target of semaglutide, and the glucagon receptor. Innovent describes it as an analog of oxyntomodulin, a gut hormone that activates both receptors naturally.
Its registered structure (FDA GSRS, UNII MB76Z4IBZ5) is a 34-residue chain with three modifications: aminoisobutyric acid at position 2, the same DPP-4-resistant substitution semaglutide carries, a C20 fatty diacid attached through a linker to the lysine at position 20, and an amidated C-terminus. The fatty acid binds albumin and extends its half-life.
The glucagon arm is what separates it from GLP-1-only compounds. Glucagon receptors are concentrated in the liver, where Innovent attributes reduced fat synthesis and increased fat breakdown to their activation, and oxyntomodulin itself lowers body weight in humans by raising energy expenditure as well as reducing food intake. Retatrutide adds GIP-receptor activity to the same pair.
Innovent's Phase 3 trials enrolled Chinese adults, and GLORY-1 used Chinese BMI thresholds for overweight and obesity.
In DREAMS-3, Innovent reported that 48.0% of mazdutide participants reached both an HbA1c below 7% and at least 10% weight loss at week 32, versus 21.0% with semaglutide. For GLORY-1, Innovent's week-48 figure for the higher dose was 14.8% versus 0.5%, under the efficacy estimand.
Outside China, a Lilly-funded Phase 2 trial in 179 US adults (Lancet Diabetes & Endocrinology, 2026) tested higher doses and reported weight reductions of up to 18.1% at 32 weeks versus 0.9% with placebo.
According to Innovent, China's National Medical Products Administration approved mazdutide for chronic weight management on June 27, 2025, and for glycemic control in type 2 diabetes in September 2025. It is sold in China as Xinermei, and Innovent describes it as the world's first GLP-1/glucagon dual agonist approved for weight management.
Mazdutide is not approved by the FDA. As of October 2026, ClinicalTrials.gov lists Lilly-sponsored mazdutide trials through Phase 2, including the US obesity trial above and a study in alcohol use disorder, and no Lilly Phase 3 trial.
In the US it is investigational, with no USP monograph and no approved product containing it, so it is not eligible for compounding by a 503A pharmacy or a 503B outsourcing facility. The FDA bulk-substance proceedings that decide the status of older research peptides do not reach it.
Survodutide, from Boehringer Ingelheim, is a second GLP-1/glucagon dual agonist that has completed Phase 3 obesity trials. The two share a mechanism but are distinct molecules: survodutide is a 29-residue chain carrying a C18 fatty diacid, mazdutide a 34-residue chain carrying a C20 diacid. Their trials enrolled different populations for different durations, so their weight-loss figures are not directly comparable.
No. Mazdutide is not approved by the FDA. According to Innovent Biologics, China's National Medical Products Administration approved it for chronic weight management in June 2025 and for glycemic control in type 2 diabetes in September 2025, and it is sold in China as Xinermei. As of October 2026, Eli Lilly's registered mazdutide trials had reached Phase 2. Research-grade mazdutide sold by peptide vendors is for laboratory research only, not for human consumption.
Semaglutide activates only the GLP-1 receptor. Mazdutide activates both the GLP-1 receptor and the glucagon receptor, which is concentrated in the liver and linked to fat breakdown and energy expenditure. In DREAMS-3, an open-label trial in Chinese adults with type 2 diabetes and obesity, Innovent reported that 48.0% of mazdutide participants reached a combined HbA1c and weight-loss target at 32 weeks versus 21.0% with semaglutide, which was given at a diabetes-treatment dose below its obesity dose.
Both are peptides that activate the GLP-1 and glucagon receptors, but they are different molecules from different companies. Mazdutide, from Eli Lilly and Innovent Biologics, is a 34-residue chain carrying a C20 fatty diacid and is approved in China. Survodutide, from Boehringer Ingelheim under license from Zealand Pharma, is a 29-residue chain carrying a C18 fatty diacid and is not approved anywhere. Their trials enrolled different populations for different durations, so their results are not directly comparable.
Mazdutide is sold by 8 research peptide vendors indexed on PeptideScouter, with 12 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
7 of the 8 indexed vendors currently have Mazdutide in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Glacier Aminos currently lists Mazdutide at $4.69/mg, the lowest listed price across 8 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $4.22/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 8 vendors listing Mazdutide publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $4.69/mg listed to $4.22/mg at Glacier Aminos. Each vendor's code is shown beside its price in the table above.
Mazdutide ranges from $4.69/mg to $18.75/mg across 12 listings from 8 research peptide vendors, normalized to USD per milligram and refreshed daily.
8 research peptide vendors currently list Mazdutide on PeptideScouter, with 7 in stock right now. We track 12 listings across size and kit variants.
Mazdutide's CAS Registry Number is 2259884-03-0.
